Komatsu S, Nomiyama T, Numata T, Kawanami T, Hamaguchi Y, Iwaya C, et al
Despite these encouraging trends, the market has hurdles, including due to the high cost of GLP-1 agonists, which may limit access for specific patient populations
The most well-known GLP-1 analog, semaglutide, was first approved in the US in 2017 for the treatment of type 2 diabetes as a subcutaneous injection drug called Ozempic
Ipamorelin is best suited for men seeking overall energy, recovery, and muscle gain, which secondarily enhances libido
Retrospective Study #1 The first retrospective study analyzed the medical records of 283 adult patients who were taking GLP-1 medications and had also visited the dermatology department for hair loss between 2021 and 2023